As the patent for Ozempic approaches its expiration in just 17 days, Novo Nordisk has implemented a new pricing policy for two of its semaglutide-based medications: Wegovy and Rybelsus. The company is introducing an initial free dose of Wegovy, contingent upon the user presenting a medical prescription. This medication is currently priced between R$ 900 and over R$ 2,000 depending on the concentration. Meanwhile, the price of Rybelsus has been slashed to R$ 565, which is approximately half of its previous price of around R$ 1,100. Major pharmacy chains such as Raia Drogasil, Drogaria São Paulo, and Pague Menos are already reflecting these new prices online.

The reductions apply to all dosages of Rybelsus, including 7mg, 3mg, or 14mg. However, there remains a requirement for a medical prescription to obtain these drugs. In a statement regarding this initiative, Allan Finkel, the CEO of Novo Nordisk, emphasized the goal of expanding access to treatments for patients, allowing for a broader range of medical professionals to support those in need. This strategic move is not only intended to enhance patient accessibility but may also play a significant role in the competitive landscape as generic alternatives become available with the patent expiration of Ozempic, potentially altering the dynamics of the obesity and diabetes treatment market.

With the upcoming expiration of Ozempic's patent, this pricing adjustment reflects a proactive approach from Novo Nordisk to retain its market share while simultaneously addressing affordability issues for consumers. As medications for conditions such as obesity and type 2 diabetes continue to rise in importance, this policy change could affect patient adherence to treatment regimens and reshape the landscape of pharmaceutical pricing strategies in Brazil and beyond.